Germany/Italy: Pharmaceuticals Capsule Fillers Made-in-Italy

Editor: Alexander Stark

In 2016, MG2 generated a double-digit increase, in both orders and turnover, for their capsule fillers and end-of-line solutions. The company expects this trend to continue during 2017.

Related Vendors

Visitors at the stand could make a virtual tour of the MG2 Pharma Zone.
Visitors at the stand could make a virtual tour of the MG2 Pharma Zone.
(Source: MG2)

Pian di Macina di Pianoro/Italy — MG2 reports a turnover increase of 28 % in 2016, accompanied by an increase in orders and a policy of expansion, both in terms of recruitment and in terms of research into new markets and technologies. The company turnover exceeded € 30 million, amounting to € 38.5.

According to the company, more than 2/3 of sales were generated in Europe and in North America (more than 37 % in Continental Europe, and approximately 30 % in USA and Canada). Emerging markets such as Asia and Africa become more important: sales in Egypt, for example, increased three times between 2015 and 2016. India has a consolidated share of 5 % in the company's turnover.

Typical customers of the supplier are multinational producers of generic drugs. This kind of production requires high-speed machines, capable of ensuring high production quality. In Europe, legislation has a strong influence on the investment decision of pharmaceutical companies. Currently, MG2 registers a purchases increase in Great Britain and in the Benelux countries, while Germany remains the most important country importing their capsule fillers. In 2017, the Italian supplier expects a positive trend with a “double digit” growth.

Growth Programme

The supplier has planned to raise its staff by 10 % by employing young designers and technicians. Additionally, the company has been involved in several projects with Italian and foreign companies. In particular, projects inspired by continuous manufacturing principles. These projects are being implemented by European and American multinational companies and require the cooperation of several players in the production chain from machine/spares suppliers to pharmaceutical technology experts.

R&D efforts have also been invested in a novel inhalation system: The company has been the first worldwide supplier of a dosage system, where capsules are inserted in inhalation devices, e.g. for the treatment of respiratory diseases.

During the last year, many investments were made also for the implementation of the Pharma Zone, the new area made up of three cleanrooms, where it is possible to work with active products, under real production conditions. Apart from dosage tests, Pharma Zone allows for pre and post sales services, and the production of small batches for R&D, including Pre-Clinical feasibility batches.

At the interpack, MG2 presented a virtual reality application, created to let the customer make a virtual tour of the MG2 Pharma Zone which allows him to both “touch by hand” its operation principles and understand its potentiality. “Interpack is a must-have worldwide appointment for the packaging companies of the pharmaceutical sector," says Manuela Gamberini, Vice-President of MG2. "In Düsseldorf we had an excellent feedback in terms of visitors with whom we outlined a series of projects showing actual development perspectives".


At the trade fair, the company showcased for instance the capsule filler Model Planeta 200, which has been presented in its version with Multinett, a net weight control system, as well as the ACE system for track&trace applications. This system is used for to the serialization of pharmaceutical packaging, and boasts of a reduced footprint and simple integration in existing lines.